SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (AMEX: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, today announced that Jack Lief,
president and chief executive officer, and a founder and director of Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA), was named Chairman of ADVENTRX.
"I'm very pleased to accept the position as Chairman of ADVENTRX. I
hope my knowledge and experience continues to prove valuable as ADVENTRX
progresses with its Phase 3 clinical trial of ANX-510 and as the company
continues to move other product candidates into the clinic that also hold
significant potential to provide patients better treatment options,"
commented Jack Lief, president and CEO of Arena.
Mr. Lief joined ADVENTRX's board of directors in September 2006 and
also serves on the board of directors of Accumetrics, Inc., a developer and
marketer of diagnostic tests, ReqMed Company, Ltd., a provider of
partnering opportunities, R&D strategies and bio-venture funding, and
TaiGen Biotechnology Co., Ltd., a biotechnology company. In addition, Mr.
Lief is an executive board member for BIOCOM, a life science industry
association representing more than 450 member companies in San Diego and
Southern California, and from March 2005 to March 2006, served as chairman
of BIOCOM.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that directors will undertake projects that divert
their respective attention from ADVENTRX matters, or that may pose a
conflict of interest with ADVENTRX; ADVENTRX's ability to raise sufficient
capital to fund the projects necessary to meet its anticipated or stated
goals; the ability to timely enroll subjects in ADVENTRX's current and
anticipated clinical trials; the results of pending clinical trials for
CoFactor(R) or ADVENTRX's other product candidates; the potential for
CoFactor(R) and ADVENTRX's other product candidates to receive regulatory
approval for one or more indications, and the uncertain process of seeking
regulatory approval; other difficulties or delays in developing, testing,
manufacturing and marketing and obtaining regulatory approval for
CoFactor(R) and ADVENTRX's other product candidates; unexpected adverse
side effects or inadequate therapeutic efficacy of CoFactor(R) or
ADVENTRX's other products; and other risks and uncertainties more fully
described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at http://www.sec.gov. ADVENTRX
does not intend to update any forward- looking statement, including as set
forth in this press release, to reflect events or circumstances arising
after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/comp/920134.html /
CONTACT:
investors, Ioana C. Hone of ADVENTRX,
+1-858-552-0866
|
